Open Payments

Henry Ford Hospital

Type
Teaching hospital
Where
Detroit, MI
Medicare CCN
230053
Received
$22,578,842 in 2,255 records, 2025 ($2,374,187 general, $20,204,655 research)
Source
CMS Open Payments search ↗

By year

Program yearKindRecordsAmount
2025General payment306$2,374,187
2025Research payment1,949$20,204,655

By company

CompanyRecordsAmountYears
PFIZER INC.97$2,405,6302025
Theratechnologies Inc.4$1,832,5792025
Abbott Laboratories213$1,614,6862025
Genentech, Inc.59$1,106,6132025
Merck Sharp & Dohme LLC53$1,006,7782025
Amgen Inc.20$998,4142025
AstraZeneca Pharmaceuticals LP64$957,2522025
AstraZeneca UK Limited7$745,8812025
Beckman Coulter, Inc.30$745,3632025
Janssen Research & Development, LLC70$637,9422025
Medtronic, Inc.52$626,8802025
ABBVIE INC.124$595,6752025
Gilead Sciences, Inc.34$586,9022025
Boston Scientific Corporation37$555,7652025
Edwards Lifesciences Corporation57$469,0972025
Siemens Medical Solutions USA, Inc.17$451,4402025
Regeneron Pharmaceuticals, Inc.67$354,2312025
Daiichi Sankyo Inc.57$352,0852025
Celgene Corporation17$321,9692025
TransMedics, Inc.5$296,7302025
SANOFI US SERVICES INC.21$267,9432025
Incyte Corporation66$255,5872025
Sequel Med Tech, LLC254$245,9932025
Becton, Dickinson and Company2$241,8612025
Eli Lilly and Company5$219,7422025
ROCHE MOLECULAR SYSTEMS, INC.4$172,0882025
SEAGEN INC.10$171,5542025
E.R. Squibb & Sons, L.L.C.20$170,0012025
BrioHealth Solutions, Inc.3$162,2512025
United Therapeutics Corporation31$149,8392025
Cepheid3$147,8892025
Servier BioInnovation49$136,0092025
Insulet Corporation2$121,9732025
PUMA BIOTECHNOLOGY, INC.5$110,4602025
ModernaTX, Inc.13$109,2362025
Ipsen Bioscience Inc.2$99,2652025
Tanabe Pharma America, Inc.32$98,9422025
Novartis Pharmaceuticals Corporation12$98,9052025
Roche Diagnostics Operations, Inc.7$96,1532025
ABIOMED11$95,6232025
Ambu A/S3$94,8502025
National Marrow Donor Program11$84,1672025
Mannkind Corporation6$78,0032025
Vasc-Alert LLC2$64,0552025
Takeda Pharmaceuticals U.S.A., Inc.19$64,0332025
INSTRUMENTATION LABORATORY COMPANY2$63,6102025
Arrow International, Inc.2$60,0482025
COLOPLAST CORP1$60,0002025
Materialise NV1$60,0002025
BioNTech SE12$59,7632025

By nature of payment

NatureRecordsAmount
Research payment1,949$20,204,655
Grant53$1,085,570
Space rental or facility fees (teaching hospital only)143$525,389
Compensation for services other than consulting, including serving as faculty or as a speaker at a v56$297,590
Consulting Fee9$194,038
Royalty or License2$114,055
Education16$77,445
Long term medical supply or device loan7$44,579
Debt forgiveness14$20,362
Gift3$13,000
Charitable Contribution1$2,000
Travel and Lodging1$96
Food and Beverage1$60

Records

DateCompanyAmountNatureFormProductStudyYear
2025-12-31PFIZER INC.$70,380Research paymentCash or cash equivalentPREVNAR 20 Biological, VACCINESA PHASE 4 STUDY USING A TESTNEGATIVE DESIGN TO EVALUATE THE EFFECTIVENESS OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE A2025
2025-12-31Merck Sharp & Dohme LLC$67,900Research paymentIn-kind items and services Biological, ONCOLOGYAn Open-label, Randomized Phase 3 Study of MK-2870 as a Single Agent and in Combination with Pembrolizumab Versus Treatm2025
2025-12-31Merck Sharp & Dohme LLC$56,170Research paymentIn-kind items and servicesXTANDI Drug, ONCOLOGYA Phase 3, Randomized, Open-label Study of MK-5684 Versus Alternative Abiraterone Acetate or Enzalutamide in Participant2025
2025-12-31Vasc-Alert LLC$54,055Royalty or License (4 payments)Cash or cash equivalent2025
2025-12-31Merck Sharp & Dohme LLC$37,491Research paymentIn-kind items and servicesKEYTRUDA Biological, ONCOLOGYA Phase 3, Randomized, Comparator-controlled Clinical Trial to Study the Efficacy and Safety of Pembrolizumab MK-3475 in2025
2025-12-31Merck Sharp & Dohme LLC$35,559Research paymentIn-kind items and servicesKEYTRUDA Biological, ONCOLOGYAn Open-label, Multicenter, Phase 3 Randomized, Active-Comparator-Controlled Clinical Study of Pembrolizumab MK-3475 in 2025
2025-12-31Merck Sharp & Dohme LLC$31,894Research paymentIn-kind items and servicesWELIREG Drug, ONCOLOGYAn Open-label, Multicenter, Phase 2 Study to Evaluate the Efficacy and Safety of Pembrolizumab Plus Lenvatinib in Combin2025
2025-12-31Merck Sharp & Dohme LLC$20,020Research paymentIn-kind items and servicesLAGEVRIO Biological, INFECTIOUS DISEASEA Phase 3, Randomized, Placebo-Controlled, Double Blind Clinical Study to Evaluate the Efficacy and Safety of Molnupirav2025
2025-12-31PFIZER INC.$19,215Research paymentCash or cash equivalentPREVNAR 20 Biological, VACCINESA PHASE 4 STUDY USING A TESTNEGATIVE DESIGN TO EVALUATE THE EFFECTIVENESS OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE A2025
2025-12-31Merck Sharp & Dohme LLC$17,540Research paymentIn-kind items and servicesKEYTRUDA Biological, ONCOLOGYA Phase III, Randomized, Open-label Study to Evaluate Pembrolizumab as Neoadjuvant Therapy and in Combination With Stand2025
2025-12-31Siemens Medical Solutions USA, Inc.$13,200Research paymentCash or cash equivalentVarian Ethos Treatment Planning Device, Oncology2025
2025-12-31Merck Sharp & Dohme LLC$11,215Research paymentIn-kind items and servicesKEYTRUDA Biological, ONCOLOGYA Phase 3, Randomized Double Blind Study to Evaluate Peri-operative Pembrolizumab MK-3475 Neoadjuvant Chemotherapy vers2025
2025-12-31Merck Sharp & Dohme LLC$10,300Research paymentIn-kind items and servicesLENVIMA Drug, ONCOLOGYA Phase 2, randomized, open-label three-arm clinical study to evaluate the safety and efficacy of lenvatinib E7080,MK-792025
2025-12-31Sequel Med Tech, LLC$8,000Research paymentCash or cash equivalentTWIIST Device, AUTOMATED INSULIN DELIVERY DEVICEInnovative Automated Insulin Delivery System for T2D2025
2025-12-31Merck Sharp & Dohme LLC$7,028Research paymentIn-kind items and servicesWELIREG Drug, ONCOLOGYAn Open-label, Randomized Phase 3 Study of MK-6482 Versus Everolimus in Participants with Advanced Renal Cell Carcinoma 2025
2025-12-31Merck Sharp & Dohme LLC$7,019Research paymentIn-kind items and servicesLENVIMA Drug, ONCOLOGYA Phase 3 Multicenter, Randomized, Double-blinded, Active-controlled, Clinical Study to Evaluate the Safety and Efficacy2025
2025-12-31Merck Sharp & Dohme LLC$5,183Research paymentIn-kind items and servicesDOCETAXEL Drug, ONCOLOGYA Phase 3, Open-label Study of Ifinatamab Deruxtecan Versus Docetaxel in Participants with Metastatic Castration-Resista2025
2025-12-31Stryker Corporation$5,056Debt forgivenessCash or cash equivalent2025
2025-12-31Merck Sharp & Dohme LLC$4,253Research paymentIn-kind items and servicesKEYTRUDA Biological, ONCOLOGYA Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy2025
2025-12-31Stryker Corporation$3,808Long term medical supply or device loanIn-kind items and servicesNA Device, INSTRUMENTS2025
2025-12-31PFIZER INC.$3,567Research paymentCash or cash equivalentLITFULO Drug, IMMUNOLOGYA PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY WITH A DOUBLEBLIND 52WEEK EXTENSION PERIOD W2025
2025-12-31ABBVIE INC.$3,537Research paymentIn-kind items and servicesRINVOQ Biological, IMMUNOLOGYA Phase 3, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Efficacy, Safety, and Tolerability of Upad2025
2025-12-31Merck Sharp & Dohme LLC$3,481Research paymentIn-kind items and servicesKEYTRUDA Biological, ONCOLOGYA Randomized, Double-blind, Placebo-controlled Phase 3 Trial of Pembrolizumab MK-3475 Versus Placebo in Participants wit2025
2025-12-31Merck Sharp & Dohme LLC$3,327Research paymentIn-kind items and servicesKEYTRUDA Biological, ONCOLOGYA Phase 3, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Pembrolizumab MK-3475 as Monotherapy in the Ad2025
2025-12-31Sequel Med Tech, LLC$3,200Research paymentCash or cash equivalentTWIIST Device, AUTOMATED INSULIN DELIVERY DEVICEInnovative Automated Insulin Delivery System for T2D2025
2025-12-31Sequel Med Tech, LLC$3,200Research paymentCash or cash equivalentTWIIST Device, AUTOMATED INSULIN DELIVERY DEVICEInnovative Automated Insulin Delivery System for T2D2025
2025-12-31Sequel Med Tech, LLC$3,200Research paymentCash or cash equivalentTWIIST Device, AUTOMATED INSULIN DELIVERY DEVICEInnovative Automated Insulin Delivery System for T2D2025
2025-12-31Sequel Med Tech, LLC$3,200Research paymentCash or cash equivalentTWIIST Device, AUTOMATED INSULIN DELIVERY DEVICEInnovative Automated Insulin Delivery System for T2D2025
2025-12-31Intuitive Surgical, Inc.$3,000Long term medical supply or device loanIn-kind items and servicesION Device, SURGERY2025
2025-12-31Sequel Med Tech, LLC$2,400Research paymentCash or cash equivalentTWIIST Device, AUTOMATED INSULIN DELIVERY DEVICEInnovative Automated Insulin Delivery System for T2D2025
2025-12-31Merck Sharp & Dohme LLC$2,273Research paymentIn-kind items and servicesKEYTRUDA Biological, ONCOLOGYA Phase III, Randomized, Double-blind Study to Evaluate Pembrolizumab plus Chemotherapy vs Placebo plus Chemotherapy as 2025
2025-12-31Sequel Med Tech, LLC$2,223Research paymentCash or cash equivalentTWIIST Device, AUTOMATED INSULIN DELIVERY DEVICEInnovative Automated Insulin Delivery System for T2D2025
2025-12-31Sequel Med Tech, LLC$2,223Research paymentCash or cash equivalentTWIIST Device, AUTOMATED INSULIN DELIVERY DEVICEInnovative Automated Insulin Delivery System for T2D2025
2025-12-31Merck Sharp & Dohme LLC$1,834Research paymentIn-kind items and servicesLENVIMA Drug, ONCOLOGYA Phase 3 Randomized, Placebo controlled Study to Evaluate the Safety and Efficacy of Pemetrexed Platinum Chemotherapy 2025
2025-12-31Stryker Corporation$1,530Debt forgivenessCash or cash equivalent2025
2025-12-31ABBVIE INC.$1,529Research paymentIn-kind items and servicesRINVOQ Biological, IMMUNOLOGYA Phase 3 randomized, placebo-controlled, double-blind program to evaluate efficacy and safety of upadacitinib in adult 2025
2025-12-31Viseon, Inc.$1,245Debt forgivenessIn-kind items and servicesMaxView System - Lateral Set Device, Spinal Surgery2025
2025-12-31Merck Sharp & Dohme LLC$1,116Research paymentIn-kind items and servicesKEYTRUDA Biological, ONCOLOGYA Phase II Trial of Pembrolizumab MK-3475 in Combination with Platinum Doublet Chemotherapy and Radiotherapy for Partici2025
2025-12-31Sequel Med Tech, LLC$960Research paymentCash or cash equivalentTWIIST Device, AUTOMATED INSULIN DELIVERY DEVICEInnovative Automated Insulin Delivery System for T2D2025
2025-12-31Sequel Med Tech, LLC$960Research paymentCash or cash equivalentTWIIST Device, AUTOMATED INSULIN DELIVERY DEVICEInnovative Automated Insulin Delivery System for T2D2025
2025-12-31Sequel Med Tech, LLC$960Research paymentCash or cash equivalentTWIIST Device, AUTOMATED INSULIN DELIVERY DEVICEInnovative Automated Insulin Delivery System for T2D2025
2025-12-31Sequel Med Tech, LLC$960Research paymentCash or cash equivalentTWIIST Device, AUTOMATED INSULIN DELIVERY DEVICEInnovative Automated Insulin Delivery System for T2D2025
2025-12-31Sequel Med Tech, LLC$666Research paymentCash or cash equivalentTWIIST Device, AUTOMATED INSULIN DELIVERY DEVICEInnovative Automated Insulin Delivery System for T2D2025
2025-12-31Sequel Med Tech, LLC$666Research paymentCash or cash equivalentTWIIST Device, AUTOMATED INSULIN DELIVERY DEVICEInnovative Automated Insulin Delivery System for T2D2025
2025-12-31ABBVIE INC.$600Research paymentIn-kind items and servicesA Phase 1 First-in-Human Study Evaluating Safety, Pharmacokinetics and Efficacy of ABBV-706 as Monotherapy and in Combin2025
2025-12-31Merck Sharp & Dohme LLC$533Research paymentIn-kind items and servicesKEYTRUDA Biological, ONCOLOGYA Phase 2a Study with Safety Run-in to Evaluate the Safety, Tolerability, and Preliminary Efficacy of FF-10832 Monothera2025
2025-12-31Sequel Med Tech, LLC$488Research paymentCash or cash equivalentTWIIST Device, AUTOMATED INSULIN DELIVERY DEVICEInnovative Automated Insulin Delivery System for T2D2025
2025-12-31Sequel Med Tech, LLC$488Research paymentCash or cash equivalentTWIIST Device, AUTOMATED INSULIN DELIVERY DEVICEInnovative Automated Insulin Delivery System for T2D2025
2025-12-31Sequel Med Tech, LLC$488Research paymentCash or cash equivalentTWIIST Device, AUTOMATED INSULIN DELIVERY DEVICEInnovative Automated Insulin Delivery System for T2D2025
2025-12-31Sequel Med Tech, LLC$488Research paymentCash or cash equivalentTWIIST Device, AUTOMATED INSULIN DELIVERY DEVICEInnovative Automated Insulin Delivery System for T2D2025
2025-12-31Sequel Med Tech, LLC$488Research paymentCash or cash equivalentTWIIST Device, AUTOMATED INSULIN DELIVERY DEVICEInnovative Automated Insulin Delivery System for T2D2025
2025-12-31Sequel Med Tech, LLC$488Research paymentCash or cash equivalentTWIIST Device, AUTOMATED INSULIN DELIVERY DEVICEInnovative Automated Insulin Delivery System for T2D2025
2025-12-31Sequel Med Tech, LLC$488Research paymentCash or cash equivalentTWIIST Device, AUTOMATED INSULIN DELIVERY DEVICEInnovative Automated Insulin Delivery System for T2D2025
2025-12-31Sequel Med Tech, LLC$488Research paymentCash or cash equivalentTWIIST Device, AUTOMATED INSULIN DELIVERY DEVICEInnovative Automated Insulin Delivery System for T2D2025
2025-12-31Sequel Med Tech, LLC$488Research paymentCash or cash equivalentTWIIST Device, AUTOMATED INSULIN DELIVERY DEVICEInnovative Automated Insulin Delivery System for T2D2025
2025-12-31Sequel Med Tech, LLC$488Research paymentCash or cash equivalentTWIIST Device, AUTOMATED INSULIN DELIVERY DEVICEInnovative Automated Insulin Delivery System for T2D2025
2025-12-31Sequel Med Tech, LLC$488Research paymentCash or cash equivalentTWIIST Device, AUTOMATED INSULIN DELIVERY DEVICEInnovative Automated Insulin Delivery System for T2D2025
2025-12-31Sequel Med Tech, LLC$488Research paymentCash or cash equivalentTWIIST Device, AUTOMATED INSULIN DELIVERY DEVICEInnovative Automated Insulin Delivery System for T2D2025
2025-12-31Sequel Med Tech, LLC$488Research paymentCash or cash equivalentTWIIST Device, AUTOMATED INSULIN DELIVERY DEVICEInnovative Automated Insulin Delivery System for T2D2025
2025-12-31Sequel Med Tech, LLC$488Research paymentCash or cash equivalentTWIIST Device, AUTOMATED INSULIN DELIVERY DEVICEInnovative Automated Insulin Delivery System for T2D2025
2025-12-31Sequel Med Tech, LLC$488Research paymentCash or cash equivalentTWIIST Device, AUTOMATED INSULIN DELIVERY DEVICEInnovative Automated Insulin Delivery System for T2D2025
2025-12-31Sequel Med Tech, LLC$488Research paymentCash or cash equivalentTWIIST Device, AUTOMATED INSULIN DELIVERY DEVICEInnovative Automated Insulin Delivery System for T2D2025
2025-12-31Sequel Med Tech, LLC$488Research paymentCash or cash equivalentTWIIST Device, AUTOMATED INSULIN DELIVERY DEVICEInnovative Automated Insulin Delivery System for T2D2025
2025-12-31Sequel Med Tech, LLC$488Research paymentCash or cash equivalentTWIIST Device, AUTOMATED INSULIN DELIVERY DEVICEInnovative Automated Insulin Delivery System for T2D2025
2025-12-31Sequel Med Tech, LLC$488Research paymentCash or cash equivalentTWIIST Device, AUTOMATED INSULIN DELIVERY DEVICEInnovative Automated Insulin Delivery System for T2D2025
2025-12-31ADVITA ORTHO, LLC$425Research paymentCash or cash equivalentEQUINOXE Device, ORTHOPAEDICCR09-005 EQUINOXE PMCF2025
2025-12-31Merck Sharp & Dohme LLC$336Research paymentIn-kind items and servicesKEYTRUDA Biological, ONCOLOGYA Randomized, Double-Blind, Phase III Study of Carboplatin-Paclitaxel,Nab-Paclitaxel Chemotherapy with or without Pembro2025
2025-12-31Merck Sharp & Dohme LLC$274Research paymentIn-kind items and servicesLAGEVRIO Biological, INFECTIOUS DISEASEA Phase 3, Randomized, Placebo-Controlled, Double Blind Clinical Study to Evaluate the Efficacy and Safety of Molnupirav2025
2025-12-31Merck Sharp & Dohme LLC$175Research paymentIn-kind items and servicesKEYTRUDA Biological, ONCOLOGYA Randomized, Double-Blind, Phase III Study of Pembrolizumab MK-3475 plus Chemotherapy vs Placebo plus Chemotherapy for 2025
2025-12-31Sequel Med Tech, LLC$146Research paymentCash or cash equivalentTWIIST Device, AUTOMATED INSULIN DELIVERY DEVICEInnovative Automated Insulin Delivery System for T2D2025
2025-12-31Sequel Med Tech, LLC$146Research paymentCash or cash equivalentTWIIST Device, AUTOMATED INSULIN DELIVERY DEVICEInnovative Automated Insulin Delivery System for T2D2025
2025-12-31Sequel Med Tech, LLC$146Research paymentCash or cash equivalentTWIIST Device, AUTOMATED INSULIN DELIVERY DEVICEInnovative Automated Insulin Delivery System for T2D2025
2025-12-31Sequel Med Tech, LLC$146Research paymentCash or cash equivalentTWIIST Device, AUTOMATED INSULIN DELIVERY DEVICEInnovative Automated Insulin Delivery System for T2D2025
2025-12-31Sequel Med Tech, LLC$146Research paymentCash or cash equivalentTWIIST Device, AUTOMATED INSULIN DELIVERY DEVICEInnovative Automated Insulin Delivery System for T2D2025
2025-12-31Sequel Med Tech, LLC$146Research paymentCash or cash equivalentTWIIST Device, AUTOMATED INSULIN DELIVERY DEVICEInnovative Automated Insulin Delivery System for T2D2025
2025-12-31Sequel Med Tech, LLC$146Research paymentCash or cash equivalentTWIIST Device, AUTOMATED INSULIN DELIVERY DEVICEInnovative Automated Insulin Delivery System for T2D2025
2025-12-31Sequel Med Tech, LLC$146Research paymentCash or cash equivalentTWIIST Device, AUTOMATED INSULIN DELIVERY DEVICEInnovative Automated Insulin Delivery System for T2D2025
2025-12-31Sequel Med Tech, LLC$146Research paymentCash or cash equivalentTWIIST Device, AUTOMATED INSULIN DELIVERY DEVICEInnovative Automated Insulin Delivery System for T2D2025
2025-12-31Sequel Med Tech, LLC$146Research paymentCash or cash equivalentTWIIST Device, AUTOMATED INSULIN DELIVERY DEVICEInnovative Automated Insulin Delivery System for T2D2025
2025-12-31Sequel Med Tech, LLC$146Research paymentCash or cash equivalentTWIIST Device, AUTOMATED INSULIN DELIVERY DEVICEInnovative Automated Insulin Delivery System for T2D2025
2025-12-31Sequel Med Tech, LLC$146Research paymentCash or cash equivalentTWIIST Device, AUTOMATED INSULIN DELIVERY DEVICEInnovative Automated Insulin Delivery System for T2D2025
2025-12-31Sequel Med Tech, LLC$146Research paymentCash or cash equivalentTWIIST Device, AUTOMATED INSULIN DELIVERY DEVICEInnovative Automated Insulin Delivery System for T2D2025
2025-12-31Sequel Med Tech, LLC$146Research paymentCash or cash equivalentTWIIST Device, AUTOMATED INSULIN DELIVERY DEVICEInnovative Automated Insulin Delivery System for T2D2025
2025-12-31Sequel Med Tech, LLC$146Research paymentCash or cash equivalentTWIIST Device, AUTOMATED INSULIN DELIVERY DEVICEInnovative Automated Insulin Delivery System for T2D2025
2025-12-31Sequel Med Tech, LLC$146Research paymentCash or cash equivalentTWIIST Device, AUTOMATED INSULIN DELIVERY DEVICEInnovative Automated Insulin Delivery System for T2D2025
2025-12-31Sequel Med Tech, LLC$146Research paymentCash or cash equivalentTWIIST Device, AUTOMATED INSULIN DELIVERY DEVICEInnovative Automated Insulin Delivery System for T2D2025
2025-12-31Sequel Med Tech, LLC$146Research paymentCash or cash equivalentTWIIST Device, AUTOMATED INSULIN DELIVERY DEVICEInnovative Automated Insulin Delivery System for T2D2025
2025-12-31Sequel Med Tech, LLC$146Research paymentCash or cash equivalentTWIIST Device, AUTOMATED INSULIN DELIVERY DEVICEInnovative Automated Insulin Delivery System for T2D2025
2025-12-31DJO, LLC$100Debt forgivenessCash or cash equivalent2025
2025-12-31Tanabe Pharma America, Inc.$70Research paymentIn-kind items and servicesA Phase 3, Multicenter, Open-label, Long-term, Extension Study to Evaluate Safety and Tolerability of Oral Dersimelagon 2025
2025-12-30Novocure Inc.$2,000Space rental or facility fees (teaching hospital only)Cash or cash equivalentOptune Lua (NovoTTF-200T) Device, Oncology2025
2025-12-29E.R. Squibb & Sons, L.L.C.$4,982Research paymentCash or cash equivalentExpanded Access Protocol (EAP) for Patients Receiving Idecabtagene Vicleucel (ide-cel) that is Non-conforming for Commer2025
2025-12-25PFIZER INC.$6,388Research paymentCash or cash equivalentELREXFIO Drug, ONCOLOGYELRANATAMAB POST TRIAL ACCESS AN OPENLABEL SINGLEARM STUDY FOR PARTICIPANTS WITH MULTIPLE MYELOMA CONTINUING FROM PFIZER2025
2025-12-25Janssen Research & Development, LLC$4,996Research paymentCash or cash equivalentA Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Ustekinumab Active Comparator-controlled Study t2025
2025-12-25ABBVIE INC.$187Research paymentCash or cash equivalentIMBRUVICA Drug, ONCOLOGYExtended Treatment Protocol for Subjects Continuing to Benefit From Ibrutinib.2025
2025-12-24United Therapeutics Corporation$1,580Research paymentCash or cash equivalentTYVASO Drug, Pulmonary Arterial Hypertension and Pulmonary Hypertension with Interstitial Lung DiseaseA Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subj2025
2025-12-24United Therapeutics Corporation$1,300Research paymentCash or cash equivalentREMODULIN Drug, Pulmonary Arterial HypertensionA PHASE 4, PROSPECTIVE, MULTICENTER, SINGLE-ARM STUDY OF A MEAN PULMONARY ARTERY PRESSURE-TARGETED APPROACH WITH EARLY A2025
2025-12-23Daiichi Sankyo Inc.$4,550Research paymentCash or cash equivalentDS7300-1892025
2025-12-23Daiichi Sankyo Inc.$3,000Research paymentCash or cash equivalentDS7300-1892025
2025-12-23Daiichi Sankyo Inc.$2,500Research paymentCash or cash equivalentDS7300-1892025
2025-12-23Daiichi Sankyo Inc.$500Research paymentCash or cash equivalentDS7300-1892025
2025-12-22Aveo Pharmaceuticals, Inc.$3,747Research paymentCash or cash equivalentFOTIVDA Drug, OncologyTiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivo2025
2025-12-22Ionis Pharmaceuticals, Inc.$2,839Research paymentCash or cash equivalentIS744CS72025
2025-12-22SANOFI US SERVICES INC.$2,000Research paymentCash or cash equivalentA Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension St2025
2025-12-22Genmab A/S$455Research paymentCash or cash equivalentEpkinly Drug, OncologyA Randomized, Open-Label, Phase 3 Trial of Epcoritamab vs Investigator's Choice Chemotherapy in Relapsed/Refractory Diff2025
2025-12-19Medtronic, Inc.$45,188Research paymentCash or cash equivalentSYMPLICITY G3 Device, Renal Denervation SystemSPYRAL AFFIRM2025
2025-12-19TransMedics, Inc.$38,125Research paymentCash or cash equivalentOrgan Care System Device, DeviceOCS Lung TOP Regisry2025
2025-12-19Takeda Pharmaceuticals U.S.A., Inc.$20,152Research paymentCash or cash equivalentTAK-279-PsO-3004 A Phase 3, multi-center, head to head Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-22025
2025-12-19Abbott Laboratories$7,495Research paymentCash or cash equivalentAMPLATZER AMULET Device, Structural HeartNCT06707688--Abbott Medical - VERITAS Study2025
2025-12-19PFIZER INC.$6,000Research paymentCash or cash equivalentELREXFIO Drug, ONCOLOGYA PHASE 12 OPENLABEL MULTICENTER STUDY TO EVALUATE A DOSING REGIMEN WITH TWO STEPUP PRIMING DOSES AND LONGER DOSING INTE2025
2025-12-19Regeneron Pharmaceuticals, Inc.$3,254Research paymentCash or cash equivalentLIBTAYO Biological, ONCOLOGYA PHASE 2 PERI-OPERATIVE TRIAL OF FIANLIMAB AND CEMIPLIMAB IN COMBINATION WITH CHEMOTHERAPY VERSUS CEMIPLIMAB IN COMBINA2025
2025-12-19Incyte Corporation$2,707Research paymentCash or cash equivalentA Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN2)2025
2025-12-19Medtronic, Inc.$2,635Research paymentCash or cash equivalentSYMPLICITY G3 Device, Renal Denervation SystemSPYRAL AFFIRM2025
2025-12-19Genentech, Inc.$2,308Research paymentCash or cash equivalentEvaluation of Fenebrutinib in RMS patients2025
2025-12-18BIOTRONIK INC.$13,000Research paymentCash or cash equivalentPK Papyrus Device, Cardiology/Vascular DiseasesPK Papyrus-Registry2025
2025-12-18Janssen Research & Development, LLC$5,228Research paymentCash or cash equivalentCARVYKTI Drug, OncologyA Phase 3 Randomized Study Comparing Bortezomib, Lenalidomide and Dexamethasone (VRd) followed by Ciltacabtagene Autoleu2025
2025-12-18BIOTRONIK INC.$552Research paymentCash or cash equivalentPK Papyrus Device, Cardiology/Vascular DiseasesPK Papyrus-Registry2025
2025-12-18BIOTRONIK INC.$552Research paymentCash or cash equivalentPK Papyrus Device, Cardiology/Vascular DiseasesPK Papyrus-Registry2025
2025-12-18BIOTRONIK INC.$552Research paymentCash or cash equivalentPK Papyrus Device, Cardiology/Vascular DiseasesPK Papyrus-Registry2025
2025-12-18BIOTRONIK INC.$552Research paymentCash or cash equivalentPK Papyrus Device, Cardiology/Vascular DiseasesPK Papyrus-Registry2025
2025-12-18BIOTRONIK INC.$552Research paymentCash or cash equivalentPK Papyrus Device, Cardiology/Vascular DiseasesPK Papyrus-Registry2025
2025-12-18BIOTRONIK INC.$552Research paymentCash or cash equivalentPK Papyrus Device, Cardiology/Vascular DiseasesPK Papyrus-Registry2025
2025-12-18BIOTRONIK INC.$552Research paymentCash or cash equivalentPK Papyrus Device, Cardiology/Vascular DiseasesPK Papyrus-Registry2025
2025-12-18BIOTRONIK INC.$552Research paymentCash or cash equivalentPK Papyrus Device, Cardiology/Vascular DiseasesPK Papyrus-Registry2025
2025-12-18BIOTRONIK INC.$552Research paymentCash or cash equivalentPK Papyrus Device, Cardiology/Vascular DiseasesPK Papyrus-Registry2025
2025-12-18BIOTRONIK INC.$552Research paymentCash or cash equivalentPK Papyrus Device, Cardiology/Vascular DiseasesPK Papyrus-Registry2025
2025-12-18BIOTRONIK INC.$552Research paymentCash or cash equivalentPK Papyrus Device, Cardiology/Vascular DiseasesPK Papyrus-Registry2025
2025-12-18BIOTRONIK INC.$552Research paymentCash or cash equivalentPK Papyrus Device, Cardiology/Vascular DiseasesPK Papyrus-Registry2025
2025-12-18BIOTRONIK INC.$552Research paymentCash or cash equivalentPK Papyrus Device, Cardiology/Vascular DiseasesPK Papyrus-Registry2025
2025-12-18BIOTRONIK INC.$552Research paymentCash or cash equivalentPK Papyrus Device, Cardiology/Vascular DiseasesPK Papyrus-Registry2025
2025-12-18BIOTRONIK INC.$552Research paymentCash or cash equivalentPK Papyrus Device, Cardiology/Vascular DiseasesPK Papyrus-Registry2025
2025-12-18BIOTRONIK INC.$552Research paymentCash or cash equivalentPK Papyrus Device, Cardiology/Vascular DiseasesPK Papyrus-Registry2025
2025-12-18BIOTRONIK INC.$552Research paymentCash or cash equivalentPK Papyrus Device, Cardiology/Vascular DiseasesPK Papyrus-Registry2025
2025-12-18BIOTRONIK INC.$552Research paymentCash or cash equivalentPK Papyrus Device, Cardiology/Vascular DiseasesPK Papyrus-Registry2025
2025-12-18BIOTRONIK INC.$552Research paymentCash or cash equivalentPK Papyrus Device, Cardiology/Vascular DiseasesPK Papyrus-Registry2025
2025-12-18BIOTRONIK INC.$552Research paymentCash or cash equivalentPK Papyrus Device, Cardiology/Vascular DiseasesPK Papyrus-Registry2025
2025-12-18BIOTRONIK INC.$552Research paymentCash or cash equivalentPK Papyrus Device, Cardiology/Vascular DiseasesPK Papyrus-Registry2025
2025-12-18BIOTRONIK INC.$552Research paymentCash or cash equivalentPK Papyrus Device, Cardiology/Vascular DiseasesPK Papyrus-Registry2025
2025-12-18BIOTRONIK INC.$552Research paymentCash or cash equivalentPK Papyrus Device, Cardiology/Vascular DiseasesPK Papyrus-Registry2025
2025-12-18BIOTRONIK INC.$552Research paymentCash or cash equivalentPK Papyrus Device, Cardiology/Vascular DiseasesPK Papyrus-Registry2025
2025-12-18BIOTRONIK INC.$552Research paymentCash or cash equivalentPK Papyrus Device, Cardiology/Vascular DiseasesPK Papyrus-Registry2025
2025-12-18BIOTRONIK INC.$552Research paymentCash or cash equivalentPK Papyrus Device, Cardiology/Vascular DiseasesPK Papyrus-Registry2025
2025-12-18BIOTRONIK INC.$552Research paymentCash or cash equivalentPK Papyrus Device, Cardiology/Vascular DiseasesPK Papyrus-Registry2025
2025-12-18BIOTRONIK INC.$552Research paymentCash or cash equivalentPK Papyrus Device, Cardiology/Vascular DiseasesPK Papyrus-Registry2025
2025-12-18BIOTRONIK INC.$552Research paymentCash or cash equivalentPK Papyrus Device, Cardiology/Vascular DiseasesPK Papyrus-Registry2025
2025-12-18BIOTRONIK INC.$552Research paymentCash or cash equivalentPK Papyrus Device, Cardiology/Vascular DiseasesPK Papyrus-Registry2025
2025-12-18BIOTRONIK INC.$357Research paymentCash or cash equivalentPK Papyrus Device, Cardiology/Vascular DiseasesPK Papyrus-Registry2025
2025-12-18BIOTRONIK INC.$357Research paymentCash or cash equivalentPK Papyrus Device, Cardiology/Vascular DiseasesPK Papyrus-Registry2025
2025-12-18BIOTRONIK INC.$357Research paymentCash or cash equivalentPK Papyrus Device, Cardiology/Vascular DiseasesPK Papyrus-Registry2025
2025-12-18BIOTRONIK INC.$357Research paymentCash or cash equivalentPK Papyrus Device, Cardiology/Vascular DiseasesPK Papyrus-Registry2025
2025-12-18BIOTRONIK INC.$357Research paymentCash or cash equivalentPK Papyrus Device, Cardiology/Vascular DiseasesPK Papyrus-Registry2025
2025-12-18BIOTRONIK INC.$357Research paymentCash or cash equivalentPK Papyrus Device, Cardiology/Vascular DiseasesPK Papyrus-Registry2025
2025-12-18BIOTRONIK INC.$357Research paymentCash or cash equivalentPK Papyrus Device, Cardiology/Vascular DiseasesPK Papyrus-Registry2025
2025-12-18BIOTRONIK INC.$357Research paymentCash or cash equivalentPK Papyrus Device, Cardiology/Vascular DiseasesPK Papyrus-Registry2025
2025-12-18BIOTRONIK INC.$357Research paymentCash or cash equivalentPK Papyrus Device, Cardiology/Vascular DiseasesPK Papyrus-Registry2025
2025-12-18BIOTRONIK INC.$357Research paymentCash or cash equivalentPK Papyrus Device, Cardiology/Vascular DiseasesPK Papyrus-Registry2025
2025-12-18BIOTRONIK INC.$357Research paymentCash or cash equivalentPK Papyrus Device, Cardiology/Vascular DiseasesPK Papyrus-Registry2025
2025-12-18BIOTRONIK INC.$357Research paymentCash or cash equivalentPK Papyrus Device, Cardiology/Vascular DiseasesPK Papyrus-Registry2025
2025-12-18BIOTRONIK INC.$357Research paymentCash or cash equivalentPK Papyrus Device, Cardiology/Vascular DiseasesPK Papyrus-Registry2025
2025-12-18BIOTRONIK INC.$357Research paymentCash or cash equivalentPK Papyrus Device, Cardiology/Vascular DiseasesPK Papyrus-Registry2025
2025-12-18BIOTRONIK INC.$357Research paymentCash or cash equivalentPK Papyrus Device, Cardiology/Vascular DiseasesPK Papyrus-Registry2025
2025-12-18BIOTRONIK INC.$357Research paymentCash or cash equivalentPK Papyrus Device, Cardiology/Vascular DiseasesPK Papyrus-Registry2025
2025-12-18BIOTRONIK INC.$357Research paymentCash or cash equivalentPK Papyrus Device, Cardiology/Vascular DiseasesPK Papyrus-Registry2025
2025-12-18BIOTRONIK INC.$357Research paymentCash or cash equivalentPK Papyrus Device, Cardiology/Vascular DiseasesPK Papyrus-Registry2025
2025-12-17PFIZER INC.$36,995Research paymentCash or cash equivalentPREVNAR 20 Biological, VACCINESA PHASE 4 STUDY USING A TESTNEGATIVE DESIGN TO EVALUATE THE EFFECTIVENESS OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE A2025
2025-12-17Bolton Medical Inc$4,561Research paymentCash or cash equivalentTREO ABDOMINAL STENT-GRAFT SYSTEM Device, ENDOVASCULAR AORTIC REPAIRTREO PAS2025
2025-12-17PFIZER INC.$3,963Research paymentCash or cash equivalentLITFULO Drug, IMMUNOLOGYA PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY WITH A DOUBLEBLIND 52WEEK EXTENSION PERIOD W2025
2025-12-17Janssen Research & Development, LLC$2,400Research paymentCash or cash equivalentA Phase 3 Randomized Study Comparing Talquetamab in Combination with Pomalidomide (Tal-P), Talquetamab in Combination wi2025
2025-12-17Novartis Pharmaceuticals Corporation$1,800Research paymentCash or cash equivalentA Rollover Extension Program (REP) to Evaluate the Long-term Safety and Tolerability of Open-Label Pelacarsen in Partici2025
2025-12-17Bolton Medical Inc$1,150Research paymentCash or cash equivalentTREO ABDOMINAL STENT-GRAFT SYSTEM Device, ENDOVASCULAR AORTIC REPAIRTREO PAS2025
2025-12-17Novartis Pharmaceuticals Corporation$775Research paymentCash or cash equivalentRandomized, Double-blind, Placebo-controlled, Multicenter Trial, Assessing the Impact of Inclisiran on Major Adverse Car2025
2025-12-16Incyte Corporation$13,000Research paymentCash or cash equivalentA phase 3, multicenter, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of tafasita2025
2025-12-16Medtronic, Inc.$7,004Research paymentCash or cash equivalentSYMPLICITY G3 Device, Renal Denervation SystemSPYRAL AFFIRM2025
2025-12-16Boston Scientific Corporation$2,225Research paymentCash or cash equivalentWATCHMAN Access System Device, WATCHMAN_ICSIMPLAAFY2025
2025-12-16Gilead Sciences, Inc.$2,153Research paymentCash or cash equivalentLivdelzi Drug, INFLAMA 52-week, Double-blind, Placebo-controlled, Randomized, Phase 3 Study Intended to Determine the Effects of Seladelpar o2025
2025-12-15Janssen Research & Development, LLC$35,500Research paymentCash or cash equivalentA Randomized, Open-label Phase 3 Study of Amivantamab + FOLFIRI Versus Cetuximab/Bevacizumab + FOLFIRI in Participants W2025
2025-12-15Janssen Research & Development, LLC$15,372Research paymentCash or cash equivalentTECVAYLI Biological, OncologyA Phase 3 Randomized Study Comparing Teclistamab in Combination with Daratumumab SC (Tec-Dara) versus Daratumumab SC, Po2025
2025-12-15Zimmer Biomet Holdings, Inc.$9Debt forgivenessCash or cash equivalent2025
2025-12-12TransMedics, Inc.$186,600Research paymentCash or cash equivalentOrgan Care System Device, DeviceOLP-2 Liver Registry2025
2025-12-12SK Life Science, Inc.$10,076Research paymentCash or cash equivalentXCOPRI Drug, NeurologyYKP3089C0492025
2025-12-12Teva Pharmaceuticals USA, Inc.$136Research paymentIn-kind items and servicesPROAIR RESPICLICK Drug, RespiratoryA Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of 2025
2025-12-11Merck Sharp & Dohme LLC$16,000Research paymentCash or cash equivalentKEYTRUDA Biological, ONCOLOGYA Phase 3, Randomized Double Blind Study to Evaluate Peri-operative Pembrolizumab MK-3475 Neoadjuvant Chemotherapy vers2025
2025-12-11Edwards Lifesciences Corporation$11,798Research paymentCash or cash equivalentTHE ENCIRCLE Trial (#2018-19)2025
2025-12-11ABBVIE INC.$6,902Research paymentCash or cash equivalentRINVOQ Biological, IMMUNOLOGYA Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Sever2025
2025-12-11Tanabe Pharma America, Inc.$6,000Research paymentCash or cash equivalentA Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Efficacy, Safety, and Tolerabilit2025
2025-12-11ABBVIE INC.$5,991Research paymentCash or cash equivalentRINVOQ Biological, IMMUNOLOGYA Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupil2025
2025-12-11Regeneron Pharmaceuticals, Inc.$4,488Research paymentCash or cash equivalentA PHASE 3, OPEN LABEL, RANDOMIZED STUDY COMPARING THE EFFICACY AND SAFETY OF ODRONEXTAMAB (REGN1979), AN ANTI-CD20 X ANT2025
2025-12-11Incyte Corporation$2,856Research paymentCash or cash equivalentA Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN2)2025
2025-12-11Tanabe Pharma America, Inc.$2,272Research paymentCash or cash equivalentA Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Efficacy, Safety, and Tolerabilit2025
2025-12-11Celgene Corporation$788Research paymentCash or cash equivalentLong-Term Follow-up Protocol for Participants Treated With Gene-Modified T Cells. A prospective study for the long-term 2025
2025-12-11Teva Pharmaceuticals USA, Inc.$533Research paymentCash or cash equivalentAlbuterol sulfate Drug, Pulmonary/Respiratory DiseasesA Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of 2025
2025-12-10Merck Sharp & Dohme LLC$70,091Research paymentCash or cash equivalentLAGEVRIO Biological, INFECTIOUS DISEASEA Phase 3, Randomized, Placebo-Controlled, Double Blind Clinical Study to Evaluate the Efficacy and Safety of Molnupirav2025
2025-12-10TransMedics, Inc.$35,800Research paymentCash or cash equivalentOrgan Care System Device, DeviceOLP Liver Registry2025
2025-12-10Mannkind Corporation$22,953Research paymentCash or cash equivalentICON-1 PHASE 3 STUDY OF THE EFFICACY AND SAFETY OF TREATMENT WITH MNKD-101, CLOFAZAMINE INHALATION SUSPENSION2025
2025-12-10Mannkind Corporation$10,750Research paymentCash or cash equivalentICON-1 PHASE 3 STUDY OF THE EFFICACY AND SAFETY OF TREATMENT WITH MNKD-101, CLOFAZAMINE INHALATION SUSPENSION2025
2025-12-10Mannkind Corporation$7,950Research paymentCash or cash equivalentICON-1 PHASE 3 STUDY OF THE EFFICACY AND SAFETY OF TREATMENT WITH MNKD-101, CLOFAZAMINE INHALATION SUSPENSION2025
2025-12-10Brainlab, Inc.$3,580GrantIn-kind items and servicesCurve and software / instruments Device, Surgical planning and navigation radiation treatment planning and positioning2025
2025-12-10Mannkind Corporation$2,500Research paymentCash or cash equivalentICON-1 PHASE 3 STUDY OF THE EFFICACY AND SAFETY OF TREATMENT WITH MNKD-101, CLOFAZAMINE INHALATION SUSPENSION2025
2025-12-10Penumbra, Inc.$558Research paymentCash or cash equivalentIndigo System Device, Peripheral InterventionSTRIKE-PE2025
2025-12-09PFIZER INC.$1,696Research paymentCash or cash equivalentELREXFIO Drug, ONCOLOGYELRANATAMAB POST TRIAL ACCESS AN OPENLABEL SINGLEARM STUDY FOR PARTICIPANTS WITH MULTIPLE MYELOMA CONTINUING FROM PFIZER2025

The latest 200 records of 2,255.

CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.

The area Census

Wayne CountyDetroit city

County outline, the place (blue), the tract (orange) and the ZIP center (dot).

In Detroit, MI, county Wayne County, MI, state Michigan; placed by its city name.

MeasurePlace (city or town)
Detroit, MI
County
Wayne County, MI
State
Michigan
Population B01003638,5301,772,25910,077,761
Population, 2020 census P1639,1111,793,56110,077,331
Median age B0100235.237.940.2
Under 18 B0100124.8%23.6%21.2%
65 and over B0100115.1%16.6%18.6%
Households B11001257,998700,5914,076,369
Foreign born B050026.6%10.3%7.2%
Median household income B19013$39,938$60,539$72,875
Median family income B19113$49,398$79,522$93,357
Per capita income B19301$24,594$34,906$40,735
Poverty rate B1700132.7%20.8%13.2%
Unemployment rate B2302514.0%8.7%5.7%
Civilian labor force B23025268,955828,8385,018,449
Mean commute (minutes) B0801324.824.724.2
Bachelor's degree or higher B1500318.1%27.6%32.4%
Housing units B25001329,393801,0834,622,236
Owner-occupied B2500350.3%64.8%73.2%
Renters B2500349.7%35.2%26.8%
Median home value B25077$83,900$178,500$231,600
Median gross rent B25064$1,074$1,132$1,129
White, not Hispanic B0300210.8%47.9%72.4%
Black B0300275.0%36.6%13.1%
Hispanic or Latino B030028.3%6.9%5.9%
Asian B030021.7%3.7%3.4%
American Indian and Alaska Native B030020.2%0.2%0.3%

Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Detroit, MI.

Comments

Anonymous: no account or email. Up to 2,000 characters, at most one link. Comments are checked automatically; some wait for review.